title: [Evaluation of efficacy of ramosetron orally disintegrating tablets and patient preference as to the dosage form in gynecological cancer chemotherapy].
abstract: The efficacy of an oral 5-HT3 antagonist, ramosetron orally disintegrating tablet (ODT), in the treatment of chemotherapy-induced emesis was investigated in 21 female patients with cancer. Patient preference for the dosage form was also investigated. Eighteen (85.7%) of 21 patients answered that ODT is easy to take. Eleven (68.8%) of 16 patients who had previously taken granisetron tablets preferred ramosetron ODT to conventional tablets. The complete suppression rate of nausea or vomiting was more than 90% for 6 days. No adverse drug reactions associated with ramosetron were observed. As ambulatory or home chemotherapy becomes frequent, the use of oral 5-HT3 antagonists rather than intravenous agents will be increased. Chemotherapy for elderly cancer patients is becoming frequently used. Considering these circumstances, it is suggested that ramosetron ODT is a palatable and useful treatment of chemotherapy-induced emesis.
authors.affiliation: Dept. of Gynecology, Seirei Hamamatsu General Hospital.
authors.forename: S
authors.initials: S
authors.lastname: Nakayama
authors.forename: Y
authors.initials: Y
authors.lastname: Torii
authors.forename: T
authors.initials: T
authors.lastname: Noda
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000188:drug therapy; D005260:Female; D017829:Granisetron / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy; D014840:Vomiting, Anticipatory / Q000188:drug therapy*
chemical_list: D000932:Antiemetics; D001562:Benzimidazoles; D017829:Granisetron; D012702:Serotonin Antagonists; C071315:ramosetron